Actively Recruiting

Age: 18Years +
All Genders
NCT05878964

Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.

Led by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Updated on 2024-10-04

420

Participants Needed

1

Research Sites

122 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The study aim to investigate the relationship between cutaneous adverse events and quality of life in patients taking immune check point inhibitor or cyclin-dependent kinase (CDK) 4 and 6 inhibitors by two steps. In the first one, it will be investigated the relationship between the skin toxicity related to the use selected therapies and the quality of life of patients already receiving these therapies for treatment of their cancer. In the second one, it will be evaluated the relationship between skin toxicity and quality of life over three months of treatment in patients initially naïve for selected therapies. Cancer included in the analysis are NSCLC, renal cancer, gastric cancer, breast cancer, bladder cancer, melanoma, squamous cell carcinoma of the head and neck.

CONDITIONS

Official Title

Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Histologically confirmed diagnosis of solid tumor
  • Able to complete quality of life questionnaires during the study
  • Signed written informed consent
  • For Group I: Currently receiving anti-PD1/PDL1/CTLA4 or CDK inhibitors for at least 3 months for any cancer type with approved treatment
  • For Group II: Eligible to start treatment with anti-PD1/PDL1/CTLA4 or CDK inhibitors approved for their cancer type
Not Eligible

You will not qualify if you...

  • Under 18 years of age
  • Presence of skin diseases or alterations before starting anti-PD1/PDL1 or CDK inhibitor treatment
  • Chronic use of steroids
  • History of psychiatric disorders or current use of antidepressants
  • Refusal to sign written informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Roberto Iacovelli

Roma, Italy, 00168

Actively Recruiting

Loading map...

Research Team

R

Roberto Iacovelli

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here